Sangamo Therapeutics, Inc.
SGMO
$0.44
$0.00-0.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.23% | 74.64% | 75.78% | 62.01% | 45.96% |
| Total Depreciation and Amortization | -23.26% | -47.95% | -54.23% | -57.82% | -58.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -54.32% | -85.28% | -87.13% | -89.97% | -88.13% |
| Change in Net Operating Assets | 244.16% | 195.95% | 189.12% | 102.38% | 94.17% |
| Cash from Operations | 33.39% | 79.29% | 78.46% | 70.14% | 50.58% |
| Capital Expenditure | 91.39% | 94.63% | 97.56% | 98.74% | 89.27% |
| Sale of Property, Plant, and Equipment | 210.74% | 1,336.22% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -100.00% | -100.00% | -79.48% | -58.67% |
| Cash from Investing | -98.33% | -98.62% | -98.90% | -75.56% | -53.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 190.58% | 104.94% | -40.34% | 85.37% | -35.95% |
| Repurchase of Common Stock | -164.03% | -182.95% | -326.68% | 6.54% | 23.22% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 192.04% | 101.03% | -49.88% | 94.52% | -36.53% |
| Foreign Exchange rate Adjustments | 16.24% | 2,429.03% | -122.65% | -238.10% | 71.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41.24% | 129.74% | -17.39% | 94.05% | 54.51% |